These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 2872812)

  • 21. Clinical trials with terazosin. General methods.
    Sperzel WD; Luther RR; Glassman HN
    Am J Med; 1986 May; 80(5B):25-8. PubMed ID: 2872803
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Side effects of terazosin in the treatment of symptomatic benign prostatic hyperplasia.
    McKiernan JM; Lowe FC
    South Med J; 1997 May; 90(5):509-13. PubMed ID: 9160069
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Terazosin: pharmacokinetics and the effect of age and dose on the incidence of adverse events.
    Somberg JC; Achari R; Laddu AR
    Am Heart J; 1991 Sep; 122(3 Pt 2):901-5. PubMed ID: 1678920
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The relationship between terazosin dose and blood pressure response in hypertensive patients.
    Achari R; Hosmane B; Bonacci E; O'Dea R
    J Clin Pharmacol; 2000 Oct; 40(10):1166-72. PubMed ID: 11028256
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Terazosin: ex vivo and in vitro platelet aggregation effects in patients with arterial hypertension.
    Hernández Hernández R; Angeli-Greaves M; Carvajal AR; Guerrero Pajuelo J; Armas Padilla MC; Armas-Hernández MJ
    Am J Hypertens; 1996 May; 9(5):437-44. PubMed ID: 8735174
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Randomized double-blind study comparing the efficacy of terazosin versus placebo in women with prostatism-like symptoms.
    Lepor H; Theune C
    J Urol; 1995 Jul; 154(1):116-8. PubMed ID: 7776406
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Terazosin: a new antihypertensive agent with favorable effects on lipids.
    Luther RR
    Int J Clin Pharmacol Ther Toxicol; 1989 Jul; 27(7):313-9. PubMed ID: 2570758
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A multicentre, hospital study of the efficacy and safety of terazosin and its effects on the plasma cholesterol levels of patients with essential hypertension.
    Lytle TB; Coles SJ; Waite MA
    J Clin Pharm Ther; 1991 Aug; 16(4):263-73. PubMed ID: 1682328
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of a 3-month treatment with terazosin on fasting and postprandial glucose and lipid metabolism in type 2 diabetic patients with hypertension.
    Pasanisi F; Imperatore G; Vaccaro O; Iovine C; Ferrara LA
    Nutr Metab Cardiovasc Dis; 1999 Apr; 9(2):73-7. PubMed ID: 10726112
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antihypertensive effectiveness of terazosin: a new long-acting alpha-adrenergic inhibitor.
    Chrysant SG; Bal IS; Johnson B; McPherson MA
    Clin Cardiol; 1985 Sep; 8(9):486-9. PubMed ID: 2864153
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Terazosin. A pharmacoeconomic evaluation of its use in benign prostatic hyperplasia.
    Plosker GL; Goa KL
    Pharmacoeconomics; 1997 Feb; 11(2):184-97. PubMed ID: 10165827
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Terazosin for benign prostatic hyperplasia.
    Wilt TJ; Howe RW; Rutks IR; MacDonald R
    Cochrane Database Syst Rev; 2002; (4):CD003851. PubMed ID: 12519611
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of terazosin on serum lipids.
    Deger G
    Am J Med; 1986 May; 80(5B):82-5. PubMed ID: 2872813
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antihypertensive dose-response relationships: studies with the selective alpha 1-blocking agent terazosin.
    Weber MA; Cheung DG; Laddu AR; Luther RR
    Am Heart J; 1991 Sep; 122(3 Pt 2):905-10. PubMed ID: 1678921
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Terazosin: a new long-acting alpha 1-adrenergic antagonist for hypertension.
    Frishman WH; Eisen G; Lapsker J
    Med Clin North Am; 1988 Mar; 72(2):441-8. PubMed ID: 2894488
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effects of terazosin and methyclothiazide on blood pressure and serum lipids.
    Luther RR; Glassman HN; Estep CB; Maurath CJ; Jordan DC
    Am Heart J; 1989 Apr; 117(4):842-7. PubMed ID: 2564723
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hemodynamic and endocrinological effects of a new selective alpha 1-blocking agent, terazosin, in patients with essential hypertension. Results of long-term treatment.
    Tomoda F; Takata M; Yoshida K; Yasumoto K; Mikawa M; Sasayama S
    Am J Hypertens; 1989 Nov; 2(11 Pt 1):834-9. PubMed ID: 2574044
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antihypertensive effects of doxazosin in systemic hypertension and comparison with terazosin.
    Hayduk K; Schneider HT
    Am J Cardiol; 1987 May; 59(14):95G-98G. PubMed ID: 2884860
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of terazosin in the treatment of benign prostatic hyperplasia.
    Elhilali MM; Ramsey EW; Barkin J; Casey RW; Boake RC; Beland G; Fradet Y; Trachtenberg J; Orovan WL; Schick E; Klotz LH
    Urology; 1996 Mar; 47(3):335-42. PubMed ID: 8633398
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The mechanism of adverse events associated with terazosin: an analysis of the Veterans Affairs cooperative study.
    Lepor H; Jones K; Williford W
    J Urol; 2000 Apr; 163(4):1134-7. PubMed ID: 10737482
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.